vaccin
effect
mean
prevent
control
viral
infect
erad
smallpox
signific
progress
made
toward
polio
erad
clear
exampl
great
impact
antivir
vaccin
howev
viral
infect
remain
major
public
health
threat
signific
caus
death
antivir
vaccin
introduc
past
centuri
empir
develop
poliomyel
measl
mump
rubella
exampl
diseas
larg
control
thank
empir
develop
vaccin
common
factor
among
effect
antivir
vaccin
develop
mimic
natur
immun
respons
pathogen
exampl
singl
episod
measl
confer
lifelong
immun
survivor
henc
need
induc
similar
immun
respons
better
mother
natur
face
substanti
challeng
develop
success
vaccin
exampl
immun
respons
virus
hiv
influenza
respiratori
syncyti
viru
rsv
either
inadequ
outpac
pathogen
evolut
develop
broadli
protect
vaccin
pathogen
coloss
task
imposs
similar
mission
success
accomplish
case
antihbv
antihpv
vaccin
grow
list
emerg
reemerg
viral
infect
effect
vaccin
yet
develop
recent
technolog
advanc
area
immunogen
design
singl
cell
transcriptom
system
biolog
gene
deliveri
epigenet
nanoparticl
adjuv
expand
understand
vaccin
work
provid
potenti
new
platform
could
har
develop
vaccin
challeng
emerg
viral
pathogen
live
viral
vaccin
live
viru
vaccin
prepar
viral
strain
attenu
retain
abil
replic
human
host
thu
abil
induc
protect
immun
respons
virus
antivir
vaccin
current
licens
unit
state
nine
live
attenu
tabl
sever
immunolog
advantag
util
live
attenu
antivir
vaccin
platform
replic
attenu
vaccin
strain
host
cell
allow
potenti
activ
antigenspecif
tcell
respons
potenti
elicit
mucos
immun
respons
eg
iga
portal
entri
mani
virus
resid
sever
method
use
attenu
viru
strain
order
safe
use
human
vaccin
one
method
depend
use
viral
strain
specif
differ
host
vaccin
strain
oldest
exampl
strategi
use
cowpox
viru
vaccin
human
smallpox
anoth
strategi
reli
attenu
viru
passag
unnatur
host
cell
exampl
approach
develop
yellow
fever
vaccin
strain
poliovirus
introduc
viru
via
unnatur
rout
strategi
use
develop
adenoviru
type
vaccin
given
oral
final
gener
temperatur
sensit
mutant
live
attenu
influenza
vaccin
inactiv
whole
viral
vaccin
whole
inactiv
viru
prepar
prepar
simpli
inactiv
viral
particl
heat
uv
irradi
special
chemic
treatment
formalin
betapropiolacton
commonli
use
chemic
purpos
vaccin
poliovirus
influenza
among
first
prepar
use
strategi
immunogen
viral
prepar
usual
robust
contain
multipl
pathogenassoci
molecular
pattern
pamp
could
engag
sever
host
innat
immun
receptor
tolllik
receptor
tlr
polio
incid
incomplet
inactiv
vaccin
prepar
result
outbreak
paralyt
poliomyel
unit
state
socal
cutter
incid
henc
safeti
prepar
alway
concern
subunit
vaccin
due
increas
risk
reactogen
associ
whole
inactiv
viru
vaccin
prepar
purifi
prepar
contain
main
target
protect
immun
respons
develop
subunit
vaccin
contain
surfac
glycoprotein
influenza
hepat
b
virus
current
licens
tabl
subunit
vaccin
show
improv
reactogen
profil
compar
whole
inactiv
viru
prepar
usual
expens
immunogen
vaccin
administ
adjuv
immun
respons
vaccin
significantli
enhanc
advanc
method
protein
manufactur
made
possibl
express
desir
viral
protein
larg
scale
use
vaccin
antigen
bacteri
yeast
insect
mammalian
cell
line
use
purpos
recombin
vaccin
contain
main
surfac
glycoprotein
influenza
virus
hemagglutinin
ha
flublok
recent
licens
unit
state
tabl
discuss
later
chapter
recombin
viral
protein
surfac
antigen
hepat
b
virus
tend
form
viruslik
particl
upon
express
viruslik
particl
vlp
vlp
multimer
structur
assembl
viral
structur
protein
often
display
viral
surfac
protein
highdens
repetit
manner
surfac
may
play
role
enhanc
immunogen
observ
kind
vaccin
compar
recombin
viral
protein
first
antivir
vlp
vaccin
hepat
b
licens
vaccin
base
hepat
b
surfac
antigen
hbsag
upon
express
yeast
form
spheric
vlp
adsorb
onto
alum
adjuv
recent
anoth
antivir
vlp
vaccin
human
papillomaviru
licens
viral
infect
broadli
classifi
three
main
categori
depend
natur
infect
acut
infect
caus
antigen
stabl
virus
infect
withor
vaccin
virus
provid
lifelong
immun
clinic
reinfect
exampl
virus
includ
smallpox
yellow
fever
measl
mump
rubella
polio
develop
effect
vaccin
virus
rel
straightforward
process
acut
infect
caus
rapidli
mutat
virus
immun
acquir
virus
infect
vaccin
usual
shortliv
antigen
chang
recurr
immun
often
requir
clearest
exampl
virus
influenza
prime
exampl
virus
develop
vaccin
virus
prove
daunt
task
two
main
effector
arm
adapt
immun
respons
induc
antivir
vaccin
mediat
protect
viral
infect
antibodi
cell
briefli
discuss
two
arm
later
chapter
import
understand
immun
effector
cytokin
secret
innat
immun
cell
activ
vaccin
coadminist
adjuv
could
also
directli
contribut
control
viral
burden
also
initi
innat
immun
recognit
vaccinesadjuv
essenti
trigger
adapt
immun
respons
also
determin
qualiti
durat
respons
given
speed
virus
replic
possess
protect
level
preform
antibodi
best
strategi
protect
viral
infect
therefor
major
immunolog
goal
antivir
vaccin
elicit
high
durabl
level
antigenspecif
antibodi
prefer
antibodi
induc
portal
viru
entri
date
human
vaccin
shown
consider
success
combat
viral
infect
depend
antibodi
primari
mediat
protect
process
gener
antibodi
start
vaccin
antigen
encount
bind
specif
b
cell
presenc
cognat
tcell
help
vaccin
specif
b
cell
start
expand
activ
b
cell
differenti
plasmablast
whose
function
secret
earli
protect
wave
antigenspecif
antibodi
primari
vaccin
earli
antibodi
mostli
igm
bind
vaccin
antigen
rel
low
affin
subset
activ
b
cell
continu
expand
form
special
organ
structur
secondari
lymph
node
known
germin
center
gc
gc
vaccinespecif
b
cell
highest
antigen
bind
affin
preferenti
select
also
major
antibodi
isotypeswitch
igm
igg
iga
occur
antibodi
protect
viral
infect
via
sever
way
induc
suffici
level
antibodi
prevent
infect
block
bind
virus
receptor
host
cell
call
neutral
antibodi
target
epitop
lie
primarili
within
surfac
glycoprotein
envelop
virus
capsid
protein
nonenvelop
one
target
epitop
neutral
antibodi
usual
conform
opson
phagocytosi
viral
particl
neutral
nonneutr
antibodi
bind
surfac
viral
particl
complement
pathway
antibodydepend
cellular
cytotox
adcc
adcc
cell
mediat
lysi
infect
cell
natur
killer
nk
cell
recogn
antibodi
label
infect
cell
via
fc
receptor
cell
respons
mainten
antigenspecif
serum
antibodi
level
follow
vaccin
infect
longliv
plasma
cell
cell
gener
germin
center
reaction
resid
mainli
bone
marrow
main
two
subset
cell
cell
least
one
two
subset
cell
particip
protect
mediat
antivir
vaccin
main
function
cell
provid
help
b
cell
clear
infect
prevent
infect
contrast
antibodi
recogn
epitop
conform
cell
recogn
linear
peptid
infect
agent
express
mhc
molecul
surfac
virusinfect
cell
peptid
come
viral
protein
exhibit
extens
antigen
variat
make
cell
import
mechan
protect
rapidli
evolv
virus
cell
contribut
antivir
vaccin
effect
sever
way
secret
cytokin
tnf
support
activ
b
cell
cell
secret
cytokin
support
bcell
activ
differenti
trigger
format
mainten
gc
reaction
via
express
secret
tfh
cell
hand
clear
viru
infect
cell
directli
kill
cell
releas
perforin
granzym
indirectli
secret
inflammatori
cytokin
tcell
control
viral
burden
thu
limit
sever
diseas
unit
state
current
licens
antivir
vaccin
work
sole
via
induct
cell
significantli
contribut
protect
effect
sever
antivir
vaccin
measl
zoster
virus
system
vaccinolog
system
biolog
integr
analysi
compon
involv
complex
biolog
process
includ
analysi
gene
eg
transcriptom
molecul
eg
proteom
cell
eg
multiparamet
flow
cytometri
perturb
cours
certain
biolog
process
activ
immun
respons
system
vaccinolog
refer
use
system
biolog
approach
analyz
human
immun
respons
vaccin
advantag
use
system
vaccinolog
approach
includ
gain
new
insight
mechan
antivir
vaccinemedi
immun
defin
new
molecular
signatur
trigger
immun
respons
variou
vaccin
adjuv
potenti
use
molecular
signatur
altern
correl
protect
moreov
appli
system
biolog
approach
highlight
import
role
play
earli
innat
immun
respons
trigger
adapt
immun
respons
variou
antivir
vaccin
role
usual
overlook
assess
effect
vaccin
use
tradit
correl
protect
tabl
analysi
immun
respons
yellow
fever
vaccin
one
earliest
exampl
util
system
vaccinolog
provid
proof
concept
approach
approach
later
appli
antivir
vaccin
influenza
summari
excit
advanc
highlight
potenti
system
biolog
transform
understand
antivir
vaccin
work
also
mechan
immun
regul
gener
multiparamet
flow
cytometri
introduct
flow
cytometri
revolution
analyz
immun
respons
allow
us
examin
physic
paramet
variou
immun
cell
cell
size
granular
differ
state
also
express
level
mani
protein
either
cell
surfac
insid
cell
simultan
analys
provid
us
enorm
insight
varieti
biolog
process
immun
cell
experi
activ
prolifer
differenti
death
respond
foreign
antigen
begin
number
fluoresc
dye
conjug
antibodi
dye
could
assign
one
molecul
could
use
simultan
limit
one
two
number
dramat
expand
past
two
decad
advanc
came
introduct
novel
fluoresc
dye
provid
addit
excit
emiss
spectra
use
perhap
one
import
insight
came
flow
cytometr
analys
defin
multipl
lineag
b
cell
elicit
variou
antivir
vaccin
also
differenti
statu
fate
lineag
chang
time
number
paramet
measur
per
cell
recent
expand
integr
mass
spectrometri
singlecel
fluidic
eg
cytof
cytof
antibodi
label
heavi
metal
ion
tag
instead
fluorochrom
anoth
major
advantag
cytof
elimin
signal
interfer
result
spectral
overlap
variou
fluoresc
dye
report
use
new
technolog
alreadi
reveal
new
insight
complex
interconnected
differ
subset
virusspecif
cell
gener
infect
provid
except
insight
immun
system
work
measur
averag
respons
sometim
highli
heterogen
cell
popul
gene
express
analys
exampl
perform
use
total
mrna
purifi
highli
heterogen
cell
popul
latter
scenario
end
result
analysi
would
probabl
bias
toward
abund
fraction
heterogen
cell
popul
larger
contribut
overal
rna
content
therefor
identifi
rare
subset
cell
use
technolog
arguabl
imposs
singlecel
rna
sequenc
rnaseq
import
extens
gene
express
array
technolog
enabl
us
interrog
genomewid
express
profil
individu
cell
mrna
unbias
way
addit
singlecel
rnaseq
reveal
transcript
featur
singl
cell
splice
variant
allelespecif
express
potenti
discoveri
previous
uncharacter
gene
dna
modif
regul
access
differ
transcript
factor
polymeras
transcript
regulatori
element
chromatin
modif
regul
gene
express
provid
cell
mechan
retain
acquir
transcript
program
throughout
cell
divis
given
essenti
role
epigenet
decid
maintain
cell
fate
huge
amount
interest
recent
given
studi
role
epigenet
immun
respons
viral
infect
vaccin
sever
aspect
immun
respons
antivir
vaccin
could
modifi
via
epigenet
defin
epigenet
program
associ
memori
b
cell
optim
qualiti
direct
differenti
immun
cell
desir
fate
eg
vs
cell
revers
undesir
fate
antigenspecif
cell
eg
rejuven
exhaust
cell
chronic
viral
infect
character
gene
express
epigenet
program
associ
antivir
vaccineinduc
memori
b
cell
provid
insight
protect
qualiti
pois
effector
recal
respons
next
gener
sequenc
also
refer
deep
sequenc
significantli
impact
analyz
mani
biolog
phenomena
immun
respons
except
regard
immun
respons
antivir
vaccin
deep
sequenc
affect
side
equat
viru
vaccin
side
adapt
immun
side
rna
virus
hiv
influenza
exist
quasispeci
introduct
deep
sequenc
technolog
afford
us
higher
resolut
look
divers
instead
analyz
individu
virus
clonal
pool
antigenspecif
b
cell
share
distinct
junction
region
form
site
bcell
receptor
bcr
heavi
tcell
receptor
tcr
beta
gene
segment
ligat
interrog
bcell
repertoir
deep
sequenc
allow
us
studi
divers
bcell
respons
viral
infect
vaccin
divers
refer
mani
distinct
clonal
pool
particip
bor
tcell
respons
particular
vaccin
particularli
import
analyz
respons
vaccin
highli
variabl
virus
influenza
hiv
virus
better
polyclon
respons
direct
sever
epitop
focus
respons
moreov
track
bcell
clonal
pool
secret
antibodi
desir
specif
qualiti
help
studi
ontogeni
evolut
respons
similar
analys
perform
alpha
beta
chain
tcr
gener
human
monoclon
antibodi
mab
year
ago
emil
von
behr
develop
passiv
immunotherapi
use
serum
treat
infect
diphtheria
tetanu
award
nobel
prize
physiolog
medicin
advent
hybridoma
technolog
introduc
concept
gener
monoclon
antibodi
singl
defin
specif
past
two
decad
tremend
effort
gone
develop
technolog
gener
human
mab
current
wide
use
methodolog
gener
human
mab
phage
display
librari
name
indic
phage
design
express
singlechain
variabl
antibodi
fragment
scfv
antigenbind
fragment
fab
surfac
screen
bind
desir
antigen
librari
construct
variabl
gene
b
cell
isol
vaccin
individu
convalesc
patient
method
success
use
gener
neutral
mab
mani
virus
includ
west
nile
rabi
sever
acut
respiratori
syndrom
sar
viru
hepat
hiv
ebola
yellow
fever
hepat
c
measl
influenza
major
drawback
method
use
examin
repertoir
immunodomin
hierarchi
antigenspecif
bcell
respons
antibodi
fragment
display
gener
random
pair
bcr
heavi
light
chain
natur
exist
pair
b
bcell
immort
b
cell
immort
epsteinbarr
viru
ebv
mediat
transform
immort
b
cell
stimul
secret
antibodi
antibodi
screen
desir
specif
bcell
pool
secret
desir
antibodi
clone
limit
dilut
singl
cell
bcr
gene
sequenc
method
use
gener
mab
mani
virus
includ
influenza
hiv
sar
dengu
rsv
method
effect
isol
mab
rare
memori
b
cell
laborintens
requir
screen
thousand
immort
memori
b
cell
order
isol
mab
desir
specif
c
singl
cell
clone
express
mab
recent
technolog
also
effici
approach
heavi
light
chain
gene
singlecel
sort
b
cell
amplifi
clone
antibodi
express
vector
singl
antigenspecif
b
cell
sort
flow
cytometri
base
surfac
phenotyp
eg
sort
plasmablast
blood
follow
vaccin
base
bind
desir
antigen
human
mab
expand
understand
human
bcell
respons
viral
infect
gener
mab
follow
variou
viral
infect
vaccin
abl
map
viral
target
protect
immun
respons
importantli
reveal
subdomin
epitop
within
viral
protein
extens
examin
discuss
later
chapter
target
broadli
neutral
mab
potenti
core
new
immunogen
structurebas
immunogen
design
mention
earlier
design
immunogen
use
antivir
vaccin
alway
empir
process
immunogen
pick
base
abil
elicit
detect
protect
immun
respons
process
suffici
mani
virus
challeng
virus
hiv
influenza
deeper
analysi
epitop
target
neutral
antibodi
need
tradit
way
determin
amino
acid
residu
within
viral
protein
recognizedand
thu
mediat
viru
neutralizationbi
certain
mab
gener
viral
escap
mutant
method
instrument
map
major
neutral
epitop
within
influenza
ha
molecul
howev
method
sever
drawback
neutral
mab
fail
gener
escap
mutant
influenza
broadli
neutral
mab
recogn
ha
stem
region
discuss
later
chapter
therefor
could
map
use
approach
increas
risk
logist
difficulti
associ
gener
escap
mutant
certain
virus
highli
pathogen
avian
influenza
virus
ebola
given
major
neutral
mab
recogn
conform
epitop
identifi
singl
amino
acid
residu
contribut
bind
provid
complet
pictur
chang
amino
acid
residu
escap
mutant
necessarili
mean
residu
point
contact
viral
protein
mab
chang
epitop
conform
induc
chang
adjac
amino
acid
residu
could
also
respons
gener
escap
mutant
first
crystal
structur
viral
glycoproteinantibodi
complex
publish
solv
structur
mani
viral
glycoprotein
allow
us
examin
bind
antibodi
respect
epitop
atom
level
importantli
provid
basi
ration
design
viral
immunogen
couldat
least
theoreticallyinduc
immun
respons
enrich
antibodi
desir
specif
idea
recent
test
partial
success
effort
gener
target
antibodi
respons
hiv
rsv
influenza
earli
experi
also
reveal
work
need
fulli
understand
complex
epitop
recogn
b
cell
vivo
minim
design
immunogen
without
interrupt
stabil
protein
antigen
epitop
dnaand
rnabas
vaccin
concept
use
nake
dna
vaccin
introduc
earli
rapidli
gain
traction
mainli
due
simplic
versatil
earli
clinic
trial
demonstr
safeti
dna
vaccin
also
reveal
poorli
immunogen
immunogen
dna
vaccin
improv
differ
method
improv
effici
dna
deliveri
enhanc
cellular
uptak
plasmid
dna
use
adjuv
either
physic
form
encod
separ
plasmid
optim
sequenc
dna
vaccin
enhanc
express
immunogen
encod
protein
dna
vaccin
varieti
virus
test
differ
stage
clinic
trial
advanc
method
mrna
synthesi
stabil
pave
way
possibl
use
mrna
vaccin
platform
abil
mrna
stimul
sever
innat
immun
receptor
eg
give
intrins
adjuv
activ
approach
boost
recent
introduct
selfamplifi
rna
strategi
work
deliv
alphaviru
gene
encod
rna
replic
machineri
along
recombin
viral
target
antigen
result
enhanc
antigen
express
vectorbas
vaccin
vectoredbas
vaccin
could
consid
type
dna
vaccin
attenu
viru
bacterium
use
introduc
microbi
dna
host
cell
commonli
use
viru
vector
adenovirus
alphavirus
poxvirus
bacteria
strain
belong
bacillu
calmetteguerin
listeria
monocytogen
salmonella
typhi
test
vector
human
vaccin
viral
pathogen
effect
vaccin
yet
licens
broadli
group
two
categori
challeng
virus
emerg
virus
exampl
challeng
virus
hiv
hcv
rsv
cmv
ebv
dengu
varieti
reason
develop
effect
vaccin
viral
pathogen
formid
task
despit
tremend
effort
great
amount
resourc
gone
develop
vaccin
hiv
mission
prove
arduou
far
challeng
prospect
discuss
later
chapter
influenza
effect
vaccin
season
potenti
pandem
influenza
viru
strain
licens
howev
vaccin
discuss
later
chapter
offer
broad
protect
rapidli
evolv
virus
vaccin
candid
rsv
dengu
enter
advanc
stage
clinic
test
tabl
emerg
viral
pathogen
includ
ebola
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
hendra
nipah
marburg
chikungunya
lassa
crimeancongo
hemorrhag
fever
zika
virus
infect
virus
limit
certain
endem
area
turn
make
decis
develop
vaccin
virus
econom
favor
one
howev
wake
massiv
ebola
outbreak
ravag
west
africa
percept
could
chang
ebola
recent
studi
suggest
robust
immun
respons
could
detect
convalesc
patient
indic
develop
protect
vaccin
pathogen
doabl
inde
mani
vaccin
candid
shown
promis
result
clinic
trial
two
candid
readi
phase
test
antivir
vaccin
advanc
stage
clinic
test
includ
vaccin
develop
cmv
noroviru
later
chapter
discuss
challeng
face
develop
vaccin
hiv
influenza
univers
rsv
recent
technolog
advanc
could
help
overcom
challeng
effort
develop
vaccin
hiv
start
fact
still
licens
vaccin
yet
despit
plethora
resourc
invest
show
enorm
task
challeng
imped
develop
vaccin
hiv
stem
follow
point
like
rna
virus
hiv
virus
continu
mutat
evolv
lead
emerg
new
variant
even
within
infect
individu
necessit
vaccin
success
elicit
immun
respons
enough
breadth
protect
extens
divers
correl
protect
hiv
infect
well
establish
common
factor
virus
vaccin
success
develop
know
immun
effector
mediat
protect
correl
protect
usual
defin
analyz
immun
respons
individu
recov
infect
show
less
suscept
infect
complet
recoveri
hiv
infect
common
occurr
least
partial
viru
infect
cell
orchestr
two
arm
adapt
immun
respons
b
cell
cell
knowledg
gap
regard
proteinport
viral
protein
antigen
immunogen
thu
best
suit
vaccin
antigen
also
whether
specif
structur
conform
requir
protein
elicit
protect
immun
respons
clear
disappoint
result
earli
vaccin
design
sole
induc
tcell
respons
refocus
antihiv
vaccin
effort
gener
protect
broadli
neutral
antibodi
respons
notion
augment
modest
success
hiv
vaccin
trial
conduct
part
vi
new
approach
need
vaccin
thailand
subject
prime
replicationdefect
canarypox
viral
vector
express
hiv
gag
pol
protein
later
boost
protein
rate
hiv
infect
among
subject
receiv
experiment
vaccin
lower
volunt
receiv
placebo
correl
protect
antibodi
respons
region
hiv
envelop
protein
later
establish
vivo
antihiv
antibodi
could
protect
sever
way
neutral
cellfre
virion
block
celltocel
transmiss
clear
infect
cell
antibodydepend
cellmedi
cytotox
adcc
block
transcytosi
virion
lumen
basolater
side
mucos
cell
fig
trial
observ
result
sharp
increas
number
broadli
neutral
antihiv
human
mab
isol
character
sequenc
analysi
antibodi
structur
examin
interact
hiv
antigen
atom
level
strengthen
understand
broadli
neutral
antibodi
work
exampl
know
broadli
neutral
antibodi
like
either
unusu
long
loop
extrem
high
rate
somat
hypermut
extens
research
effort
current
focus
learn
elicit
antibodi
vaccin
target
pursu
differ
angl
use
structur
inspir
immunogen
mimic
epitop
broadli
neutral
mab
hope
get
bcell
immun
respons
domin
antibodi
earli
trial
indic
addit
structur
requir
may
need
desir
epitop
recogn
vivo
present
epitop
right
conform
possibl
need
special
immun
strategi
depend
sequenti
expos
immun
system
differ
close
relat
hiv
envelop
protein
idea
mimic
immun
system
chronic
hivinfect
individu
experi
rapidli
evolv
viru
end
develop
broadli
neutral
antibodi
subset
extens
deep
sequenc
analysi
ontogeni
broadli
neutral
antibodi
allow
us
dissect
affin
matur
step
requir
attain
level
reactiv
sequenc
approach
would
help
us
defin
characterist
immunogen
use
sequenti
immun
strategi
discuss
earlier
summari
new
technolog
advanc
taught
us
hiv
exist
swarm
virus
evolv
rapidli
within
infect
individu
deep
sequenc
analysi
immun
system
capabl
gener
potent
broadli
neutral
mab
could
combat
viral
divers
gener
human
mab
design
new
immunogen
enrich
b
cell
respons
hiv
vaccin
broadli
neutral
antibodi
structurebas
immunogen
design
earliest
trial
develop
influenza
vaccin
date
back
shortli
isol
first
human
influenza
viru
inactiv
whole
viru
prepar
develop
us
militari
use
world
war
ii
although
earli
vaccin
protect
control
infect
mediat
respiratori
pathogen
continu
repres
formid
challeng
dilemma
stem
everevolv
natur
influenza
virus
enabl
virus
escap
preexist
immun
surveil
moreov
effect
vaccin
influenza
virus
work
elicit
antibodi
respons
primarili
target
globular
head
ha
variabl
among
viru
protein
therefor
necessari
perform
annual
revis
antigen
includ
human
season
influenza
vaccin
part
vi
new
approach
need
vaccin
ensur
match
circul
influenza
strain
current
season
influenza
vaccin
includ
antigen
three
influenza
b
four
two
influenza
b
human
influenza
viru
strain
need
broadli
protect
influenza
vaccin
clearli
demonstr
occasion
failur
season
influenza
vaccin
control
annual
epidem
influenza
virus
result
million
case
sever
ill
death
worldwid
seriou
scenario
influenza
virus
caus
occasion
pandem
antigen
novel
viru
spill
human
popul
case
pandem
viru
influenza
viru
ceas
circul
among
human
decad
reemerg
major
neutral
epitop
locat
around
receptorbind
domain
within
influenza
ha
globular
head
region
fig
antibodi
target
epitop
protect
mostli
strainspecif
lack
broad
neutral
activ
requir
protect
differ
influenza
subtyp
structur
analysi
number
recent
isol
broadli
neutral
human
haspecif
mab
reveal
bound
conserv
domain
within
ha
stem
region
fig
mab
isol
phage
display
librari
direct
clone
singl
cell
sort
plasmablast
follow
influenza
infect
vaccin
unlik
case
hiv
influenza
broadli
neutral
antibodi
could
detect
follow
infect
vaccin
therefor
remain
puzzl
despit
repeatedli
expos
conserv
domain
influenza
ha
either
form
vaccin
natur
infect
influenza
remain
seriou
public
health
problem
one
possibleamong
manyexplan
puzzl
concentr
ha
stemspecif
antibodi
low
prevent
infect
notion
support
observ
mab
target
stem
region
weaker
gener
target
head
epitop
term
vitro
neutral
potenc
question
boost
stemspecif
respons
level
protect
vivo
recent
data
suggest
convent
season
vaccin
induc
bcell
respons
domin
target
ha
head
region
therefor
new
immunogen
would
need
refocu
respons
target
ha
stem
region
use
immunogen
compris
globular
head
region
ha
molecul
deriv
virus
wide
circul
human
popul
avian
influenza
virus
combin
stem
region
conserv
among
strain
chang
domin
immun
respons
head
focus
stem
focus
globular
head
region
significantli
differ
circul
human
virus
stem
region
larg
conserv
idea
engag
stemspecif
memori
b
cell
minim
interfer
head
specif
one
strategi
inde
succeed
boost
stemspecif
respons
question
regard
whether
boost
enough
afford
protect
vivo
yet
address
addit
boost
aforement
trial
restor
globular
head
immunodomin
bcell
respons
suggest
globular
head
region
might
intrins
immunogen
stem
counterpart
similar
hiv
effort
focus
design
structurebas
immunogen
present
broadli
neutral
epitop
within
ha
stem
within
receptorbind
domain
immun
system
relev
conform
discuss
earlier
gold
standard
design
success
antivir
vaccin
mimic
natur
infect
scenario
could
appli
case
rsv
natur
rsv
infect
provid
limit
protect
reinfect
therefor
develop
protect
vaccin
rsv
daunt
task
global
public
health
prioriti
decad
antigen
variabl
major
obstacl
develop
broadli
protect
vaccin
hiv
influenza
two
serotyp
rsv
crossreact
antibodi
could
readili
detect
human
sera
major
hurdl
hinder
develop
licens
vaccin
rsv
vaccineenhanc
diseas
phenomenon
first
note
formalininactiv
vaccin
candid
firsv
develop
test
infant
children
late
immunogen
result
promis
howev
upon
natur
rsv
infect
firsvvaccin
subject
hospit
wherea
control
group
requir
admiss
two
children
die
formid
task
get
right
balanc
vaccin
safeti
immunogenicityefficaci
especi
vulner
highest
prioriti
target
popul
infant
lack
ideal
anim
model
make
clinic
trailswhich
expens
time
consumingan
imper
measur
assess
candid
vaccin
addit
clinic
endpoint
evalu
rsv
vaccin
efficaci
specif
diseas
symptom
share
mani
respiratori
viral
infect
base
epidemiolog
burden
rsv
diseas
four
target
popul
rsv
vaccin
infant
month
children
month
pregnant
women
elderli
popul
present
challeng
term
immun
system
respond
variou
vaccin
candid
sever
type
rsv
vaccin
develop
mani
other
pipelin
fig
mani
vaccin
still
preclin
stage
four
type
vaccin
platform
test
phase
trial
fig
live
attenu
viru
vaccin
particlebas
vaccin
vlp
subunit
vaccin
vectorbas
vaccin
vaccin
platform
advantag
disadvantag
mostli
share
focu
elicit
antibodi
respons
rsv
f
glycoprotein
palivizumab
human
mab
specif
f
glycoprotein
proof
principl
neutral
antibodi
could
provid
protect
hospit
palivizumab
licens
use
infant
high
risk
sever
diseas
recent
structur
insight
gain
solv
atom
structur
preand
postfus
form
f
protein
invigor
rsv
vaccin
develop
effort
know
mani
neutral
fspecif
antibodi
bind
postfus
form
f
protein
actual
specif
prefus
form
moreov
novel
antigen
site
term
reveal
antibodi
target
epitop
show
potent
neutral
capac
compar
palivizumab
effort
focus
prepar
physic
stabl
vaccin
candid
compris
nativ
f
protein
trimer
prefus
form
multipl
factor
contribut
lack
licens
protect
vaccin
particular
viru
factor
origin
natur
viru
exampl
includ
virus
exhibit
extens
genet
variat
eg
influenza
virus
evolv
multipl
mechan
evad
host
immun
detect
respons
eg
hcv
hsv
virus
integr
genom
host
eg
hiv
virus
capabl
develop
latenc
hsv
factor
stem
inabl
host
protect
infect
reinfect
due
inadequaci
immun
respons
eg
rsv
factor
unrel
viru
host
includ
lack
anim
model
suitabl
evalu
efficaci
vaccin
candid
econom
consider
earli
antivir
vaccin
success
stori
eg
smallpox
rabi
yellow
fever
base
empir
effort
vaccin
deriv
either
live
attenu
form
viru
inactiv
whole
viru
clear
approach
enough
address
current
challeng
develop
effect
vaccin
mani
current
challeng
virus
would
requir
integr
effort
scientist
repres
variou
disciplin
exampl
public
health
studi
would
need
assess
diseas
burden
differ
popul
order
defin
vulner
one
virolog
studi
would
import
gener
viral
vaccin
strain
lack
immun
evas
capac
exampl
immunologist
would
defin
arm
immun
respons
need
achiev
protect
bioinformatician
would
need
work
close
immunologist
order
transform
highthroughput
data
analys
concret
use
knowledg
structur
analys
would
help
identifi
import
immun
target
ration
design
immunogen
elicit
maxim
immun
respons
target
vaccinologist
would
assess
vaccin
candid
preclin
clinic
trial
final
engag
pharmaceut
industri
would
essenti
scale
product
final
product
